Study identifies 3 existing drugs that may help treat COVID-19

If COVID-19 research has taught us anything, it’s this: scientists love a shortcutespecially the legal,
FDA-regulated kind. Instead of inventing a brand-new drug from scratch (a process that can take years),
researchers often “repurpose” medicines that already exist. Think of it as rummaging through the world’s
biggest medicine cabinet and asking, “Okay, what in here might also work against SARS-CoV-2?”

One study did exactly thatusing a clever mix of computer screening and lab testingand flagged
three existing drugs as potential candidates for early-phase COVID-19 treatment:
amodiaquine, zuclopenthixol, and nebivolol.
Before anyone starts treating their home pharmacy like a DIY clinical trial (please don’t), let’s unpack what
the research actually found, why it matters, and how it fits into the real-world COVID-19 treatment landscape.

Why scientists keep raiding the “already-approved” medicine cabinet

Speed mattersespecially in an outbreak

Drug development is usually a marathon. Repurposing is more like showing up on race day with a bicycle and a
suspiciously detailed map. When a medication is already used in humans, researchers often have valuable
information about dosing, side effects, interactions, and manufacturing. That doesn’t make it automatically
safe or effective for COVID-19but it can make the “could this work?” question faster to test.

But “promising” doesn’t equal “proven”

The pandemic also delivered a hard lesson in scientific humility: lab results can be exciting…and still fail in
real people. A drug might slow a virus in a dish yet do nothing clinically, or require doses that would be unsafe
for patients. COVID-19 headlines sometimes skip that nuance, which is how we end up with social media arguments
that sound like a pharmaceutical version of sports talk radio.

So here’s the framing you want as you read the rest of this article:
These three drugs were identified as candidates based on early-stage evidence (computer + lab work), not as
confirmed COVID-19 treatments.

Meet the study: from computer predictions to lab proof-of-concept

The researchers started with a simple idea: if a drug shares key structural features with another compound that’s
been heavily studied, maybe it could show similar biological behavior. They used hydroxychloroquine
as a reference “template,” then searched a large library of already-approved drugs for molecules with similar
structural patterns. The result was a shortlist of candidates worth testing in a lab.

Next came the reality check: the team ran in vitro experiments (meaning: in cells, not in humans).
Several candidates were evaluated for whether they could reduce SARS-CoV-2 infection in cell-based assays.
In that screening, zuclopenthixol and nebivolol showed the ability to block infection
at low micromolar concentrations, and amodiaquineplus its active metabolitewas discussed
as having notable antiviral potential in related assays.

The important takeaway is not “we found a cure.” The takeaway is:
the workflow narrowed thousands of approved drugs down to a few plausible candidates with measurable lab activity.
That’s what drug repurposing is supposed to dogenerate testable leads quicklythen hand them off to the slower,
stricter world of clinical trials.

The three candidate drugs, translated into plain English

Let’s meet the trio. Each comes from a totally different part of medicinebecause viruses don’t care about your
pharmacy aisle categories.

1) Amodiaquine (antimalarial)

What it is: Amodiaquine is an antimalarial drug used in some regions, often as part of combination
therapy for malaria. It’s in the same broad “quinoline” family neighborhood that includes other antimalarial drugs.

Why it popped up in COVID-19 screening: The study’s approach was anchored to hydroxychloroquine-like
features, and amodiaquine’s chemistry made it a plausible match. The research discussion highlighted amodiaquine and
its active metabolite as having antiviral activity in lab contexts (including viral titer reduction work described in
the paper’s summary).

Why it’s not a simple swap: Even if a medication has antiviral activity in vitro, using it for COVID-19
raises practical questions: Is it widely available in the U.S.? Is it routinely prescribed here? Do the doses that might
matter for SARS-CoV-2 overlap with doses that are safe for patients?

Bottom line: Amodiaquine is a scientifically interesting lead, but it’s not a standard U.S. outpatient
COVID-19 medicationand “interesting” is not the same as “recommended.”

2) Zuclopenthixol (typical antipsychotic)

What it is: Zuclopenthixol is a “typical” (first-generation) antipsychotic used for certain psychiatric
conditions in some countries. It’s not a household-name medication in the U.S., which is an important point when readers
interpret “existing drug.”

What the study suggested: In the lab screening described by the researchers, zuclopenthixol was among the
compounds that could block SARS-CoV-2 infection at low micromolar concentrations in cell assays.

Safety reality check: Antipsychotic medications can carry significant side effect burdens and interaction risks.
Even if a compound shows antiviral activity in vitro, the tolerability profile might make it a poor fit for widespread use
in viral infectionsespecially in older adults or people with complex medical histories (a group already at higher risk for severe COVID-19).

Bottom line: Zuclopenthixol is a strong example of why repurposing is both exciting and complicated:
lab signal first, human suitability second.

3) Nebivolol (beta-blocker for high blood pressure)

What it is: Nebivolol is a beta-blocker used to treat hypertension (high blood pressure). Unlike the first two,
this one is much more familiar in U.S. clinical practice.

What the study found in vitro: Nebivolol was one of the candidates reported to block SARS-CoV-2 infection in
cell assays at low micromolar concentrations, with confirmatory experiments noted in the research summary.

What makes it intriguing: Cardiovascular health matters in COVID-19 outcomes, and nebivolol’s established role
in hypertension means its safety profile is well characterized for its intended use. But that does not mean it’s safe
or effective as an antiviraldifferent purpose, different dosing logic, different risk/benefit calculation.

Bottom line: Nebivolol stands out as a “familiar” drug with a lab signalbut clinical proof would still be required
before anyone could call it a COVID-19 therapy.

So…are these drugs used to treat COVID-19 right now?

In mainstream U.S. clinical guidance, the answer is: not as standard outpatient antivirals.
For people at higher risk of severe disease, current outpatient treatment emphasizes early antiviral therapy
started quicklygenerally within days of symptom onset. The point is to reduce the chance of hospitalization and death.

In real-world U.S. care, the main outpatient options have centered on medications such as:

• Nirmatrelvir/ritonavir (Paxlovid) an oral antiviral taken early, with important drug–drug interaction considerations.
• Remdesivir (Veklury) an IV antiviral given over a short outpatient course when oral options can’t be used.
• Molnupiravir (Lagevrio) an alternative oral antiviral generally reserved for situations where preferred options aren’t appropriate.

In addition, certain immunocompromised individuals may have access to pre-exposure prophylaxis options as an added layer of protection,
depending on evolving authorizations and variant susceptibility patterns.

That’s the key context: the “three-drug” study is about candidate discoverynot current standard-of-care replacement.
It’s the start of a pipeline, not the finish line.

What the study means (and what it doesn’t)

What it means

• Drug repurposing can be systematic. The study used a repeatable screening approach: computational similarity search plus lab validation.
• Lab activity can prioritize clinical questions. Instead of “test everything,” researchers can focus on a few candidates with measurable signals.
• It keeps the therapeutic pipeline diverse. COVID-19 treatment benefits from multiple optionsespecially when variants shift, supply chains wobble,
  or drug interactions limit who can safely take what.

What it doesn’t mean

• It does not prove these drugs work in people with COVID-19. In vitro success is only step one.
• It does not mean you should ask for these drugs “just in case.” Off-label use without evidence can cause harm and complicate care.
• It does not replace existing recommended antivirals. If you’re eligible for evidence-based outpatient treatment,
  that’s the lane to stay in.

A quick “how to read COVID drug headlines” checklist

The next time you see a headline like “Existing drug may treat COVID-19,” run it through these questions:

1. Was it tested in peopleor only in cells/animals?
2. Is there a randomized clinical trial? Observational results can be misleading.
3. What dose was used? Lab concentrations don’t always map to safe human dosing.
4. Who benefits? Early infection vs. hospitalized disease are different biological battles.
5. Does guidance recommend it? If not, the story may be “interesting,” not “actionable.”

How repurposed drugs actually make it to the finish line

Successful repurposing usually follows a familiar sequence:

• Step 1: Computational prediction or high-throughput screening generates candidates.
• Step 2: In vitro testing confirms whether there’s real antiviral (or host-target) activity.
• Step 3: Pharmacology checks: can the needed concentrations be achieved safely in humans?
• Step 4: Clinical trials determine whether patients actually improve (and whether harms emerge).
• Step 5: Guidelines incorporate results when the evidence is strong and consistent.

This study is best placed at Steps 1–2, with hints toward Step 3. That’s valuablebecause without early filtering, you’d have a “clinical trial wish list”
the size of a Costco parking lot.

What to watch next

If you’re following COVID-19 therapeutics, here’s what tends to matter more than buzz:

• Clinical trial registration and results: Do candidates move from “lab signal” to human testing?
• Combination strategies: Antiviral “cocktails” can reduce resistance risk and broaden effectiveness.
• Equitable access: Treatments only save lives if people can get them quicklyespecially within the early symptom window.
• Variant-aware prevention: For immunocompromised patients, prophylaxis options may shift as variants evolve.

Experiences from the repurposing roller coaster (about )

If you lived through the early pandemic years, you probably remember how drug repurposing felt from the outside:
part hope, part confusion, part “why is my uncle forwarding me a PDF that looks like it was faxed in 1997?”
In real life, repurposing wasn’t just a scientific strategyit became a shared cultural experience.

For clinicians, one common experience was the constant tension between urgency and evidence. When hospitals were full
and families were scared, every potential therapy sounded like a lifeline. But medicine doesn’t run on vibes; it runs
on outcomes. Doctors had to explain (often repeatedly) that a drug showing promise in a petri dish isn’t the same as a
drug that prevents a patient from needing oxygen. Those conversations were especially hard when a headline had already
convinced someone that “the cure exists, they just won’t use it.”

For patients, the experience was often logistical as much as medical. Once effective outpatient antivirals entered the
picture, the new challenge became timing: you had to test quickly, recognize symptoms early, contact a provider, and
start treatment within a narrow window. That created a very modern kind of anxietyless “what if I get sick?” and more
“what if I get sick on a weekend, my doctor’s office is closed, and my pharmacy is out of stock?” In that context,
research into additional optionswhether brand-new antivirals or repurposed candidatesfelt like a pressure release valve.

Researchers, meanwhile, experienced the upside and downside of speed. On the upside: unprecedented collaboration,
rapid data sharing, and the ability to screen huge libraries of existing drugs using modern computational methods.
On the downside: the public got a front-row seat to science in progressmeaning they also saw false starts in real time.
Repurposing studies, especially computational ones, sometimes landed in the public conversation before the words “clinical
endpoint” had even entered the chat. The result was a mismatch between what the study actually claimed (“this is a candidate”)
and what people heard (“this works”).

The “three existing drugs” study sits right in the middle of that lived experience. It reflects the best version of
repurposing culture: organized, testable, and honest about being early-stage. It also reminds us why the process matters.
COVID-19 isn’t one static disease; it changes with variants, immunity levels, and population risk profiles. Having more than
one therapeutic pathwaymore than one way to keep people out of the hospitalmakes a health system more resilient.

In other words, repurposing isn’t about magic bullets. It’s about building a deeper bench. And if there’s one pandemic lesson
worth keeping, it’s that you always want depth on the benchbecause viruses do not care that you are tired.

Conclusion

The study identifying amodiaquine, zuclopenthixol, and nebivolol as potential
COVID-19 candidates is a snapshot of science doing what it does best: turning a huge problem into a testable shortlist.
It doesn’t prove these drugs treat COVID-19 in humansbut it does show how repurposing can surface plausible leads quickly.
In the meantime, evidence-based outpatient antivirals and preventive strategies remain the practical tools clinicians rely on
to reduce severe outcomesespecially when started early.